Dr Christoph Willi > CMS von Erlach Partners Ltd. > Zurich, Switzerland > Lawyer Profile

CMS von Erlach Partners Ltd.
Dreikönigstrasse 7
PO Box 8022 Zurich
Switzerland

Work Department

Life Science and Health Care

Position

Partner

Career

Christoph Willi’s practice focuses on advising companies that provide medical services or manufacture and distribute medical products and medical devices in Switzerland. He is an elected, part-time judge at the Federal Patent Court.

Due to his long-standing experience in advising medical service providers, Christoph Willi is very familiar with the specifics of the highly regulated Swiss healthcare system. His in-depth knowledge of the industry allows him to develop tailor-made solutions for companies operating in the healthcare and medical sector, thereby giving his clients a competitive advantage.

Christoph Willi represents his clients before all authorities and courts in Switzerland. He uses the experience he gained as a part-time judge at the Federal Patent Court in his advocacy work for the companies he advises.

Languages

German, English, Italian, French

Memberships

  • Zurich Bar Association (ZAV)
  • Swiss Bar Association (SAV)
  • Licensing Executive Society (LES)
  • Institute for the Protection of Intellectual Property (INGRES)
  • International Association for the Protection of Intellectual Property (AIPPI)
  • Swiss Forum for Communications Law (SF)

Education

  • 1998 – Master of Laws (LL.M.), Columbia University in New York (USA)
  • 1996 – Doctorate (Dr.iur.), University of Zurich
  • 1993 – Admitted to the bar of the Canton of Zurich
  • 1990 – Law degree (lic.iur.), University of Zurich

Lawyer Rankings

Switzerland > Healthcare and life sciences

CMS von Erlach Partners Ltd. houses a broad offering which notably acts for Bayer, Eli Lilly, and Unilabs, often leveraging its international network of offices. The team also handles advertising-focused proceedings and cross-border acquisitions. Team co-leads Patrick Sommer routinely advises on M&A and administrative proceedings concerning antitrust pricing issues, and Christoph Willi is well-equipped to handle series financing matters and patent portfolio management mandates.